Internal Medicine, Hematology & Oncology · Omaha, NE
NPI
1538149414
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
17607 Gold Plz
Omaha, NE, 68130
Phone (402) 991-8468
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.4M
88,294 services
Medicare patients, 2024
655
Average age 75
Drug cost, 2024
$11.4M
1,520 prescriptions
Company payments, 2025
$139K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Luke T Nordquist was code Q9967 (low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml), 26,150 times for 146 patients. In total Luke T Nordquist billed 88,294 services in 81 codes, and Medicare paid $3.4M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-16.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 26,150 | 146 | $0.10 | $2,593 |
| J0897 Injection, denosumab, 1 mg | Office | 10,680 | 47 | $20.22 | $216K |
| J9043 Injection, cabazitaxel, 1 mg | Office | 2,921 | 15 | $167.26 | $489K |
| 36415 Venipuncture Blood Collection | Office | 1,819 | 581 | $8.61 | $16K |
| 84153 Clinical Chemistry | Office | 1,570 | 534 | $17.93 | $28K |
| 84403 Clinical Chemistry | Office | 1,446 | 514 | $25.21 | $36K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,344 | 29 | $0.07 | $96.19 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 1,330 | 163 | $137.75 | $183K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,304 | 25 | $0.09 | $116 |
| 85025 Blood Count | Office | 991 | 300 | $7.57 | $7,502 |
| 99214 Office E&M - Established | Office | 923 | 342 | $89.17 | $82K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 831 | 440 | $10.88 | $9,043 |
| 99213 Office E&M - Established | Office | 744 | 336 | $55.90 | $42K |
| A9596 Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie | Office | 455 | 77 | $853.91 | $389K |
| 96402 Chemotherapy Administration | Office | 438 | 164 | $23.44 | $10K |
By year: 2022 $4.9M for 110,033 services; 2023 $5.1M for 99,398 services; 2024 $3.4M for 88,294 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,819 | 581 | $8.61 | $16K |
| 84153 Clinical Chemistry | 1,570 | 534 | $17.93 | $28K |
| 84403 Clinical Chemistry | 1,446 | 514 | $25.21 | $36K |
| 85025 Blood Count | 991 | 300 | $7.57 | $7,502 |
| 82565 Clinical Chemistry | 320 | 167 | $5.01 | $1,604 |
| 81003 Clinical Chemistry | 32 | 23 | $2.20 | $70.4 |
| 81001 Clinical Chemistry | 22 | 19 | $3.11 | $68.42 |
Medicare prescription drug claims, 2024
In 2024, the drug Luke T Nordquist prescribed most often to Medicare patients was Xtandi (Enzalutamide), with 540 prescriptions and refills. In total Luke T Nordquist wrote 1,520 Medicare prescriptions that cost $11.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xtandi Enzalutamide | 540 | 540 | 82 | $7.3M |
| Abiraterone Acetate Generic | 249 | 249 | 34 | $181K |
| Prednisone Generic | 199 | 214 | 42 | $843 |
| Nubeqa Darolutamide | 167 | 167 | 19 | $2.2M |
| Bicalutamide Generic | 90 | 148 | 22 | $1,999 |
| Erleada Apalutamide | 83 | 83 | Under 11 | $1.2M |
| Orgovyx Relugolix | 68 | 68 | 11 | $173K |
| Ondansetron Hcl Generic | 33 | 35 | 22 | $282 |
| Megestrol Acetate Generic | 18 | 44 | Under 11 | $607 |
| Dexamethasone Generic | 18 | 18 | Under 11 | $615 |
| Letrozole Generic | 16 | 22 | Under 11 | $195 |
Brand drugs: 881 claims; generic drugs: 639 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Luke T Nordquist $139K ($135K in general payments such as food, travel and fees and $3,573 for research) from 19 companies. The largest payer was Novartis Pharmaceuticals Corporation with $138K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.